Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links
PHARMA - PARITEC CO PROMOTION

Glaxo inks co-promotion pact with Eisai for Paritec

laxoSmithkline (GSK) Pharmaceuticals Ltd has signed a co-promotion pact with Eisai Pharmaceuticals India to distribute Paritec in India. 

BY OUR PHARMA CORRESPONDENT

 

20 June, 2005: GlaxoSmithkline (GSK) Pharmaceuticals Ltd has signed a co-promotion pact with Eisai Pharmaceuticals India to distribute Paritec in India. Paritec is a proton pump inhibitor discovered and developed by Eisai Co Ltd.

Paritec has global sales of $1.3 billion and the product is known as Pariet in Japan and Aciphex in US. In India, however, the product will be subject to competition from nearly 40 generic products.

The product is approved for the treatment of acid-related disorders like peptic ulcer and reflex gastric disorders (GERD). Eisai Co is amongst the top five research-based Japanese pharmaceutical companies in Japan.

It is the first Japanese pharmaceutical major to enter India through a 100 per cent subsidiary consequent to the enactment of Patent Act by the country.

Eisai Pharma is the Indian arm of Eisai Company of Japan. The subsidiary, based in Mumbai, was set up in 2004 with a capital of Rs 10 crore. Eisai has a joint venture with Wockhardt to market its product for treating nerve disorders in diabetes patients.

GlaxoSmithKline managing director S Kalyanasundaram said, "GSK has a strong presence in the gastro-intestinal market and enjoys immense goodwill among the medical fraternity on account of Zantac. In rabeprazole, we will have an excellent molecule that will effectively fulfill unmet patient needs and allow us offer a product in a high-growth market segment.”

"I am optimistic that Paritec will be a market leader in two to three years," he said. Though Glaxo hinted that Paritec may be priced higher than its Zantac, an anti-ulcer product, Kalyanasundaram said the new drug will have an affordable price tag for local customers.

He, However, refused to comment on the revenue-share agreement. Eisai vice-president (global pharmaceuticals business) Hideshi Honda said: "India is a growing market and we have decided to collaborate with GSK because of its large distribution network and capability to build brands".

"There are over 40 generics available, but we are committed to making Paritec a market leader in two to three years' time," Kalyanasundaram said.

Eisai also has a promotion deal with Indian drug-maker Wockhardt for Methycobal, a nerve disorder drug.

BY OUR PHARMA CORRESPONDENT



 

Pharma News Headlines

Cancer News

Cardiac News

US FDA News

Pharma industry news

LATEST UPDATES

Roche, Novartis lead on novel cancer therapies

US FDA grants fast track status for GSK’s HIV drug

Stem Cell Bill could be delayed in US

FDA warning on abortion drug Mifeprex (Mifepristone)

US FDA recalls Baxter’s intravenous pumps

US FDA grants tentative nod to Ranbaxy’s glimepiride

Lupin launches generic ceftriaxone in US

Hormonal contraceptives safe for long-term use: WHO

Abortion pill to carry 'black box' warning

Vaccines not linked to autism, say experts

Novartis acquires Bristol-Myers’ OTC business in US

Guidant alerts on flaw in pacemakers

Awareness on Medicare drug benefit scheme low in US

NIH review finds govt scientists having ties with pharma firms

US FDA to decide on Plan B morning-after pill by Sept 1

Painkiller patch Duragesic under US FDA probe over patients deaths

Legionnaire's disease outbreak in US hospital in New Rochelle 

Genepharm in pact with 3 Australian distributors 

UK has new generics reimbursement scheme 

Teva gets US FDA nod for mirtazapine anti-depressant 

US patent office rejects Pfizer’s Lipitor claims 

Aethlon Medical to start trials on HIV device in India 

Panel to decide fate of Advair, Serevent and Foradil asthma drugs 

Prohibitive costs mar cancer therapy 

FDA directs Palladone withdrawal

Blindness alert on impotence drugs  

Novartis files for breast cancer drug in US, Europe  

Merck readies for $10 billion Vioxx battle  

Speak up on menopause, campaign urges US women 

Direct-To-Consumer ads mislead patients: US Senator  

EU to decide on sops for developing kids drugs  

Zidovudine by Ranbaxy gets US FDA tentative nod

Parkinson's Disease therapy triggers gambling in some patients

Parkinson's Disease symptoms may be relieved by Azilect

Are obesity and diabetes just accelerated aging?

Reducing lung infection and inflammation due to Cystic Fibrosis

Viruses may help cure cancer by killing cancer cells

New product relieves tooth pain resulting from dental sensitivity 

Cervical Cancer detector may improve on Pap Smears

Dietary supplement capsule by Liqing banned in US

Cold Stone Creamery cake batter ice-creams recalled

Guidant defibrillator recall: US FDA makes three classifications

AIDS drug stavudine by Aurobindo Pharma gets tentative US FDA approval for PEPFAR

Gates Foundation donates for a good cause

Paxil CR resupply in US pharmacies announced by GlaxoSmithKline

Viagra users not at risk of blindness: Pfizer

Stem cell research gets boost from Li Ka-shing

BiDil heart failure drug for black patients approved

Restless leg syndrome could be messing up your sleep

Glaxo Smithkline in pact with IAVI to develop AIDS drug

Pfizer acquires Vicuron Pharma for $1.9 billion

German Remedies launches Fludara Oral

Ranbaxy acquires generic product portfolio from Efarmes

Sandoz files seven ANDAs of drugs going off-patent

Elder Pharma plans unit, brand acquisition

Novasite Pharma buys PsyCheNomicS

Chemokine gets US patent for novel cancer drug

Roche gets USFDA approval for oral Xeloda

Nectar Lifesciences plans Rs 90 crore IPO 

Glaxo inks co-promotion pact with Eisai for Paritec

Early Intervention required to Prevent Diabetes

AIDS drug ahoy!

Novartis launches AMD patient counselling programme

Nanobac Life Sciences, UCSF to study kidney stones 

Surface Logix commences phase I trial for PDE-5 inhibitor

Temasek sets up $112 million pharma JV

Contraceptive from Neem, courtesy DRDO  

US FDA to source anti-HIV drugs from Indian firms  

Chemists boycott Glaxo, Novartis products  

Maharashtra phases out nerve tissue-based rabies vaccine  

Last long, really long - new sex drug soon  

Johnson and Johnson demonstrates coronary stent safety

Novartis has better breast cancer treatment

Pfizer's investigational drug reduces tumor growth

New labeling for beta-blocker Coreg 

Glaxo applies for FDA approval for Flaurix

Investigational drug for Acute Bipolar Mania And Schizophrenia

Preclinical Data Support Link Between IL-9 and Airway Hyperresponsiveness Associated With Asthma

 

 

Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links

Latest updates    Contact Us - Feedback    About Us